Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • A515U  (1)
  • CT scans  (1)
  • H1-antagonist  (1)
  • 1
    Electronic Resource
    Electronic Resource
    Tolerance and pharmacokinetics of A515U, an acyclovir analogue, in healthy volunteers (1984)
    Springer
    European journal of clinical pharmacology 27 (1984), S. 471-475 
    Details
    ISSN: 1432-1041
    Keywords: acyclovir ; A515U ; 6-deoxyacyclovir ; pharmacokinetics ; prodrug ; antiviral chemotherapy ; healthy volunteers
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary A515U (6-deoxyacyclovir) is an analogue of acyclovir devoid of antiviral activity in vitro but which is well absorbed and undergoes conversion to acyclovir after oral administration to rats. The tolerance and pharmacokinetics of various doses of A515U have been studied in 8 healthy volunteers. Single oral doses of 25, 50, 100, 200 and 400 mg A515U and 400 mg acyclovir for comparison were administered to the volunteers at weekly intervals. Concentrations of the parent drug and acyclovir were determined in plasma and urine. The prodrug was well tolerated and did not cause adverse reactions or changes in haematological or biochemical variables. It was well absorbed and conversion to acyclovir was rapid and extensive at all doses. Plasma concentrations of acyclovir achieved with 50 mg A515U orally were comparable to and less variable than those produced by 400 mg acyclovir. A515U was rapidly cleared with a short plasma elimination half life of approximately 0.5 h. The attainment of high plasma concentrations of acyclovir by oral administration of a prodrug may represent an important advance in antiviral chemotherapy.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00549597
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    The onset of effect of the H1-antagonist acrivastine (“Semprex”) assessed by histamine bronchial challenge in volunteers (1990)
    Springer
    European journal of clinical pharmacology 39 (1990), S. 311-313 
    Details
    ISSN: 1432-1041
    Keywords: acrivastine ; H1-antagonist ; histamine bronchial challenge ; onset of effect
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary The onset of effect of acrivastine, a new H1-antagonist, has been assessed using antagonism of histamine-induced bronchoconstriction in sensitive volunteers. Acrivastine administered 30, 45, 60 or 90 min before challenge produced a right-shift of the histamine dose-response curve of at least 8-fold indicating that a clinically desired degree of H1-antagonism was present within 30 min of ingestion of the recommended therapeutic dose.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00315119
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Brain metastases from colon cancer (1983)
    Springer
    Journal of neuro-oncology 1 (1983), S. 203-209 
    Details
    ISSN: 1573-7373
    Keywords: brain ; metastasis ; brain metastasis ; colon cancer ; radiation therapy ; CT scans
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Between 1977 and 1980 we evaluated 40 patients who developed brain metastases from colon cancer (4% of total patients with colon cancer). The brain metastasis was discovered in only one patient prior to cancer diagnosis; all others had known colon cancer for 2 to 48 months (median 24.5 months) prior to neurologic presentation. The colon tumor was left-sided in 32; 32 had regional lymph node metastases at neurological presentation; 37 patients had extensive systemic metastasis as well as the brain lesion. Median survival from onset of therapy for brain metastasis was 9 weeks in 32 radiation therapy (RT) treated patients (range, 2–57 weeks), 37 weeks in 7 surgically resected patients (2–84 weeks), and 4 weeks (3.5 weeks) in 2 chemotherapy patients. Follow-up CT scans were improved in 2 of 11 radiated patients. Five of 6 surgically treated patients with CT follow-up demonstrated recurrent tumor (median 4 months). The prognosis for patients with brain metastasis in colon cancer is poor, regardless of therapy.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00165604
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...